ReveraGen BioPharma Inc Initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy

Enrollment has begun in the Phase 2a clinical trial of vamorolone (VBP15) in the treatment of boys with Duchenne muscular dystrophy (DMD). The Phase 2a trial sponsored by ReveraGen BioPharma, is an open-label, multiple ascending dose study that will be followed by a 2a extension trial. The Phase 2a trials are part of the VISION-DMD project: An Innovative Steroid-like Intervention on DMD.